Diagnostic whole-body scanning before radioiodine therapy for pulmonary metastases of differentiated thyroid cancer: Predictive value and recommendations

Clinical Nuclear Medicine

Volumn 33, Issue 12, 2008, Pages 845-851

  Tachi, Yasushi ^a,c   Iwano, Shingo ^a   Kato, Katsuhiko ^a   Tadokoro, Masanori ^b   Naganawa, Shinji ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Lung metastases; Radioiodine therapy; Thyroglobulin; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; BLOOD; HEALTH CARE PLANNING; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; THYROID TUMOR; TREATMENT OUTCOME; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 58749096554     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31818bf146     Document Type: Article

References (34)

1. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metas-tases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxford). 2005;63:87-93.
2. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab. 1999;84:4043-4049.
3. Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol. 1984;57:323-327.
4. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivar-iate statistical analysis of prognostic variables. J Nucl Med. 1993;34: 1626-1631.
5. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer. 1984;53:982-992.
6. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18:600-604.
7. Samaan NA, Schultz PN, Haynie TP, et al. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab. 1985;60:376-380.
8. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598-605.
9. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. CA Cancer J Clin. 1990;40:299-317.
10. Hindie E, Melliere D, Lange F, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mole Imaging. 2003;30:974-981.
11. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin. 1998;37:30-32.
12. Park HM, Perkins OW, Edmondson JW, et al. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49-54.
13. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid. 1997;7:277-280.
14. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-1891.
15. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:629-634.
16. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 2000;85:175-178.
17. Koh JM, Kim ES, Ryu JS, et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol (Oxf). 2003,58:421-427.
18. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
19. Menzel C, Grunwald F, Schomburg A, et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med. 1996;37:1496-1503.
20. Pace L, Klain M, Albanese C, et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur J Nucl Med Mol Imaging. 2006;33:179-183.
21. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-1492.
22. Sisson JC, Jamadar DA, Kazerooni EA, et al. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid. 1998;8:215-221.
23. Tenenbaum F, Corone C, Schlumberger M, et al. Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroid-ectomy for differentiated thyroid carcinoma in patients with no evidence of disease. Eur J Cancer. 1996;32A:1262.
24. van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol. 2003; 148:589-596.
25. Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005;46:1164-1170.
26. Cholewinski SP, Yoo KS, Klieger PS, et al. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med. 2000;41:1198-1202.
27. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7:183-187.
28. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinomax. Eur J Nucl Med. 1998;25:242-246.
29. Dam HQ, Kim SM, Lin HC, et al. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527-533.
30. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer. 1996;78: 2184-2192.
31. Bal CS, Kumar A, Chandra P, et al. Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid. 2004;14:217-225.
32. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998;8:737-744.
33. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318-4323.
34. Grunwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555-1558.